

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

NOVO NORDISK INC. and
NOVO NORDISK A/S,

Plaintiffs,

v.

APOTEX INC.,

Defendant.

Civil Action No. 1:24-cv-09729
(RMB) (AMD)
(Consolidated)

Electronically Filed

NOVO NORDISK INC. and
NOVO NORDISK A/S,

Plaintiffs,

v.

APOTEX INC.,

Defendant.

Civil Action No. 1:26-cv-06553
(RMB) (AMD)

Electronically Filed

ORDER CONSOLIDATING CASES FOR ALL PURPOSES

Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S (collectively, “Novo Nordisk”), and Defendant Apotex Inc. (“Apotex,” and collectively with Novo Nordisk, the “Parties”), by and through their respective undersigned counsel, have agreed to the following stipulation, subject to the approval of the Court:

WHEREAS, on October 10, 2024, Novo Nordisk initiated a Hatch-Waxman action in this District against Apotex, relating to Apotex’s ANDA No. 219837 that references Novo Nordisk’s Rybelsus® (the “Rybelsus Tablet Litigation”) (Civil Action No. 1:24-cv-09729, ECF No. 1);

WHEREAS, on February 20, 2026, Novo Nordisk initiated a Hatch-Waxman action in related Civil Action No. 1:26-cv-01730 in this District against Apotex, relating to Apotex's ANDA No. 221238 that references Novo Nordisk's Rybelsus[®] R2 tablets, now known as Ozempic[®] tablets (the "Ozempic Tablet Litigation") (Civil Action No. 1:26-cv-01730, ECF No. 1);

WHEREAS, on March 2, 2026, this Court entered an Order consolidating the Rybelsus Tablet Litigation and Ozempic Tablet Litigation for all purposes, including discovery, case management, and trial (Civil Action No. 1:24-cv-09729, ECF No. 113);

WHEREAS, Novo Nordisk received notice of Apotex's new ANDA No. 221537 referencing Novo Nordisk's Wegovy[®] tablets by letter dated April 29, 2026, and filed a new Complaint in Civil Action No. 1:26-cv-06553 in this District against Apotex on June 4, 2026 (the "Wegovy Tablet Litigation");

WHEREAS, the Parties agree that consolidation of the above-captioned actions will promote judicial economy and conserve the Court's and the Parties' time and resources because the three actions involve the same parties, the same active ingredient and absorption enhancer, and overlapping asserted patents; and

WHEREAS, the Parties respectfully request that the Rybelsus Tablet Litigation, Ozempic Tablet Litigation, and Wegovy Tablet Litigation be consolidated because good cause exists to consolidate pursuant to Federal Rule of Civil Procedure 42;

NOW THEREFORE, IT IS HEREBY STIPULATED AND AGREED by and between the Parties, subject to approval of the Court, that:

1. Civil Action Nos. 1:24-cv-09729 and 1:26-cv-06553 (together, the "Consolidated Actions") are consolidated for all purposes, including discovery, case management, and trial, subject to further order of the Court;

2. Civil Action No. 1:24-cv-09729 shall be designated the Lead Action and the caption for the Lead Action shall be maintained as follows:

NOVO NORDISK INC. and NOVO NORDISK A/S, Plaintiffs, v. APOTEX INC., Defendant.	Civil Action No. 1:24-cv-09729 (RMB) (AMD) (Consolidated)
---	--

3. All counsel who have been admitted *pro hac vice* in either the Lead Action or the Consolidated Actions shall be deemed to be admitted *pro hac vice* in the Lead Action and Consolidated Actions, as applicable;

4. The deadline for the partes to file any responsive pleadings shall be in accordance with the Letter Order dated May 19, 2026 (Civil Action No. 1:24-cv-09729, ECF No. 135);

5. All filings in the Consolidated Actions shall use the caption of the Lead Action; and

6. All filings going forward shall be filed in the Lead Action (Civil Action No. 1:24-cv-09729), and Civil Action No. 1:26-cv-06553 shall be administratively terminated by the Clerk's office.

IT IS SO STIPULATED.

Dated: June 11, 2026

By: /s/ Liza M. Walsh

Respectfully submitted,

By: /s/ Rebekah Conroy

Liza M. Walsh
Jessica K. Formichella
Lauren R. Malakoff
WALSH PIZZI O'REILLY FALANGA LLP
Three Gateway Center
100 Mulberry Street, 15th Floor
Newark, New Jersey 07102
(973) 757-1100

OF COUNSEL
Nicholas Groombridge*
Peter Sandel*
Jenny Wu*
Daniel J. Klein*
Joshua Reich*
Ariella C. Barel*
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
565 Fifth Avenue, Suite 2900
New York, NY 10017
(332) 269-0030

Joshua Rosefelt*
Alyssa Ertel*
GROOMBRIDGE, WU, BAUGHMAN
& STONE LLP
801 17th Street, NW, Suite 1050
Washington, DC 20006
(202) 505-5830

*Admitted *pro hac vice* in Civil Action
No. 1:24-cv-09729.

*Attorneys for Plaintiffs Novo Nordisk Inc. and
Novo Nordisk A/S*

By no later than June 23, 2026, Plaintiffs shall file a consolidated amended complaint which sets forth the claims in the Rybelsus Tablet Litigation, Ozembic Tablet Litigation, and Wegovy Tablet Litigation in a single pleading.

SO ORDERED this 12th day of June, 2026

Rebekah Conroy
STONE CONROY LLC
25A Hanover Road, Suite 301
Florham Park, NJ 07932
(973) 400-4181

OF COUNSEL
William A. Rakoczy*
Rachel P. Waldron*
Joseph T. Jaros*
Katie A. Boda*
Conly S. Wythers*
Steven J. Birkos*
Nicholas D. Bortz*
Greg L. Goldblatt*
Ty Callahan*
Alejandro V. Hernandez*
RAKOCZY MOLINO MAZZOCHI SIWIK
LLP
6 West Hubbard Street, Suite 500
Chicago, Illinois 60654
(312) 527-2157

Attorneys for Defendant Apotex Inc.

s/ Renée Marie Bumb
RENÉE MARIE BUMB
Chief United States District Judge